Coronavirus / COVID

While the COVID-19 pandemic has helped advance respiratory diagnostics and surveillance, there are still many gaps that remain across the spectrum of healthcare.

The US is targeting a possible Fall rollout of publicly available doses, yet experts debate their current necessity.

Fewer than 10,000 adverse events among more than 8.9 million doses administered.

The Centers for Disease Control and Prevention (CDC) endorses the additional COVID-19 vaccine shot in immunocompromised people.

A quartet of infectious disease, vaccinology, and virology experts share thoughts on the FDA's newest emergency authorization for COVID-19 mRNA vaccines.

"Humans dislike change, especially when it is rapid, unexpected, or negative. Delta is all 3."

Donald Alcendor, PhD, shares expert perspective on the newest FDA authorization, as well as what a full COVID-19 vaccine approval would mean for US immunization.

The move will offer an extra boost of immunity for patients with compromised immune systems, including organ transplant recipients.

An England study shows the Pfizer-BioNTech and AstraZeneca vaccines remain effective in reducing symptomatic disease risk.

Three international trials combine data to find optimal heparin dosing against hypercoagulability and thrombosis in patients with COVID-19.

The Food and Drug Administration (FDA) is expected to expand the Emergency Use Authorization (EUA) of the Pfizer-BioNTech and Moderna vaccines for a third dose in those who might be vulnerable to COVID-19.

The vaccine demonstrated an acceptable safety profile in the adolescent population.

The federal agency recommends that all women who are pregnant, recently pregnant, and planning to become pregnant get the COVID-19 vaccine.

A look at the COVID-19 driven factors for this upcoming influenza season, from reopening classrooms to reduced mutation chances.

The active asthma group was not associated with a higher likelihood of mortality within 60 days.

Birth rates didn’t vary by whether the births were spontaneous or medically-indicated.

A conversation with William Schaffner, MD.

Fully vaccinated participants experienced an 80% reduction in symptomatic disease.

The study was the largest of its kind looking at the flu shot and COVID-19.

The severity and number of symptoms varied widely between individuals.

Emergency authorization may be complete before the end of August, ensuring more protection for patients burdened with certain chronic diseases.

Recent breakthrough infections have experts looking closely at the true risks of the COVID-19 delta variant and how we can protect ourselves.

Findings also showed that women had a lower risk of testing positive than men.

With the US federal government health agencies discussing plans for a booster dose for Americans and WHO’s call for a moratorium on these shots, a tale of two vaccine strategies is emerging.

The report of promising phase 2 findings align with word that an FDA submission will be delayed until later this year.

What risks and benefits need to be considered with the return of in-person classes?

Although news of the delta variant has been front and center, the lambda variant in South America is another strain that public health officials are watching.

Reviewers attribute less severe COVID-19 symptoms in patients with HIV and low CD4 count to reduced capacity for immune reactions including cytokine storm.

Contagion Editor-in-Chief Jason Gallagher, PharmD, FCCP, FIDP, FIDSA, BCPS, discusses the quick evolution of this variant and how vaccination rates have influenced this COVID-19 strain.

With the FDA nod, Regeneron’s monoclonal antibody Regen-Cov (casirivimab and imdevimab) is authorized for the use of the therapy for post-exposure prophylaxis in certain people exposed to SARS-CoV-2 or who are at high risk of exposure to an infected individual.